Stephen Farr
Chairman at Cerebral Therapeutics, Inc.
Profile
Stephen James Farr was the founder of Zogenix, Inc. (founded in 2006) and held the title of President & Chief Executive Officer.
He is currently the Chairman at Cerebral Therapeutics, Inc. (since 2018), Director at ICVRx LLC, Director at SteadyMed Therapeutics, Inc. (since 2012), Director at Zogenix International Ltd.
(since 2014), Director at Zogenix Europe Ltd., Director at Flow Pharma, Inc., Director at Oscillari LLC, Director at Tevard Biosciences, Inc., and a Member of the Royal Pharmaceutical Society of Great Britain.
Dr. Farr's former positions include Scientific Director at Novo Nordisk A, Independent Director at SteadyMed Ltd.
(2012-2018), Chief Scientific Officer & Senior Vice President at Aradigm Corp.
(1995-2006), and Professor at Welsh School of Pharmacy (1986-1994).
He holds a doctorate degree from The University of Wales and an undergraduate degree from De Montfort University.
Stephen Farr active positions
| Companies | Position | Start |
|---|---|---|
SteadyMed Therapeutics, Inc.
 SteadyMed Therapeutics, Inc. Medical/Nursing ServicesHealth Services Steadymed Therapeutics, Inc. develops drug delivery therapeutics devices. The company was founded by Amir Genosar, Ian Solomon and Gideon Kahana in 2005 and is headquartered in San Ramon, CA. | Director/Board Member | 2012-04-30 |
| ICVRx LLC | Director/Board Member | - |
Royal Pharmaceutical Society of Great Britain
 Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | - |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Director/Board Member | 2014-10-23 |
| Oscillari LLC | Director/Board Member | - |
Flow Pharma, Inc.
 Flow Pharma, Inc. Internet Software/ServicesTechnology Services Flow Pharma, Inc.operates as t-cell based vaccine delivery platform. The company was founded by Reid Rubsamen and is headquartered in Pleasant Hill, CA. | Director/Board Member | - |
Zogenix Europe Ltd.
 Zogenix Europe Ltd. Pharmaceuticals: MajorHealth Technology Part of UCB SA, Zogenix Europe Ltd. develops and commercializes pharmaceutical products. The private company is based in Lewins Mead, UK. Zogenix Europe was founded in 2010. | Director/Board Member | 2010-06-06 |
Cerebral Therapeutics, Inc.
 Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | Chairman | 2020-11-09 |
Tevard Biosciences, Inc.
 Tevard Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Tevard Biosciences, Inc. is a biotechnology company based in Cambridge, MA. Tevard Biosciences is focused on developing trna-based and other modulating therapies to cure a broad range of genetic diseases. The company is advancing the use of its novel suppressor trna, enhancer trna, and mrna amplifier platforms in neurological disorders, heart disease, and muscular dystrophies. The company was founded in 2017 by Warren Burt Lammert, Harvey F. Lodish, Daniel Fischer, and Jeffrey Coller. Daniel Fischer has been the CEO since 2017. | Director/Board Member | - |
Former positions of Stephen Farr
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
Training of Stephen Farr
| The University of Wales | Doctorate Degree |
| De Montfort University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| Private companies | 12 |
|---|---|
Aradigm Corp.
 Aradigm Corp. Pharmaceuticals: MajorHealth Technology Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
| ICVRx LLC | |
Royal Pharmaceutical Society of Great Britain
Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
SteadyMed Therapeutics, Inc.
SteadyMed Therapeutics, Inc. Medical/Nursing ServicesHealth Services Steadymed Therapeutics, Inc. develops drug delivery therapeutics devices. The company was founded by Amir Genosar, Ian Solomon and Gideon Kahana in 2005 and is headquartered in San Ramon, CA. | Health Services |
Zogenix International Ltd.
Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Zogenix Europe Ltd.
Zogenix Europe Ltd. Pharmaceuticals: MajorHealth Technology Part of UCB SA, Zogenix Europe Ltd. develops and commercializes pharmaceutical products. The private company is based in Lewins Mead, UK. Zogenix Europe was founded in 2010. | Health Technology |
SteadyMed Ltd.
 SteadyMed Ltd. Pharmaceuticals: MajorHealth Technology SteadyMed Ltd. was engaged in the research, development, and manufacture of pharmaceutical products through the PatchPump technology. Its portfolio included Trevyent for pulmonary arterial hypertension and At Home Patient Analgesia for post-surgical pains. The company was founded on June 15, 2005 and was headquartered in Rehovot, Israel. | Health Technology |
Flow Pharma, Inc.
Flow Pharma, Inc. Internet Software/ServicesTechnology Services Flow Pharma, Inc.operates as t-cell based vaccine delivery platform. The company was founded by Reid Rubsamen and is headquartered in Pleasant Hill, CA. | Technology Services |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | Commercial Services |
| Oscillari LLC | |
Tevard Biosciences, Inc.
Tevard Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Tevard Biosciences, Inc. is a biotechnology company based in Cambridge, MA. Tevard Biosciences is focused on developing trna-based and other modulating therapies to cure a broad range of genetic diseases. The company is advancing the use of its novel suppressor trna, enhancer trna, and mrna amplifier platforms in neurological disorders, heart disease, and muscular dystrophies. The company was founded in 2017 by Warren Burt Lammert, Harvey F. Lodish, Daniel Fischer, and Jeffrey Coller. Daniel Fischer has been the CEO since 2017. | Commercial Services |
- Stock Market
- Insiders
- Stephen Farr
